Associations of diabesity with all-cause and cardiovascular disease mortality: Findings from the Mexico City Prospective Study.
diabetes
mortality
obesity, cardiovascular diseases
Journal
Diabetes, obesity & metabolism
ISSN: 1463-1326
Titre abrégé: Diabetes Obes Metab
Pays: England
ID NLM: 100883645
Informations de publication
Date de publication:
05 Mar 2024
05 Mar 2024
Historique:
revised:
12
02
2024
received:
23
01
2024
accepted:
14
02
2024
medline:
5
3
2024
pubmed:
5
3
2024
entrez:
5
3
2024
Statut:
aheadofprint
Résumé
To investigate the joint associations of diabetes and obesity with all-cause and cardiovascular disease (CVD) mortality in the Mexico City Prospective Study. In total, 154 128 participants (67.2% women) were included in this prospective analysis. Diabetes was self-reported, while body mass index was used to calculate obesity. Using diabetes and obesity classifications, six groups were created: (a) normal (no diabetes and normal weight); (b) normal weight and diabetes; (c) overweight but not diabetes (overweight); (d) overweight and diabetes (prediabesity); (e) obesity but not diabetes (obesity); and (f) obesity and diabetes (diabesity). Associations between these categories and outcomes were investigated using Cox proportional hazard models adjusted for confounder factors. During 18.3 years of follow-up, 27 197 (17.6%) participants died (28.5% because of CV causes). In the maximally adjusted model, participants those with the highest risk {hazard ratio (HR): 2.37 [95% confidence interval (CI): 2.24-2.51]}, followed by those with diabesity [HR: 2.04 (95% CI: 1.94-2.15)]. Similar trends of associations were observed for CVD mortality. The highest CV mortality risk was observed in individuals with diabesity [HR: 1.80 (95% CI: 1.63-1.99)], followed by normal weight and diabetic individuals [HR: 1.78 (95% CI: 1.60-1.98)]. This large prospective study identified that diabetes was the main driver of all-cause and CVD mortality in all the categories studied, with diabesity being the riskiest. Given the high prevalence of both conditions in Mexico, our results reinforce the importance of initiating prevention strategies from an early age.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Mexican Health Ministry
Organisme : National Council of Science and Technology for Mexico
Organisme : UK Medical Research Council to the MRC Population Health Research Unit at the University of Oxford
Informations de copyright
© 2024 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.
Références
WHO. Obesity and overweight. 2021 https://www.who.int/en/news-room/fact-sheets/detail/obesity-and-overweight
Chooi YC, Ding C, Magkos F. The epidemiology of obesity. Metabolism. 2019;92:6-10.
Federation WO. The economic impact of overweight & obesity in 2020 and 2060. 2022 https://data.worldobesity.org/publications/WOF-Economic-Impacts-2-V2.pdf
Khan MAB, Hashim MJ, King JK, Govender RD, Mustafa H, Al KJ. Epidemiology of type 2 diabetes-global burden of disease and forecasted trends. J Epidemiol Glob Health. 2020;10(1):107-111.
García-Vega D, González-Juanatey JR, Eiras S. Diabesity in elderly cardiovascular disease patients: mechanisms and regulators. Int J Mol Sci. 2022;23(14):7886.
Michaelidou M, Pappachan JM, Jeeyavudeen MS. Management of diabesity: current concepts. World J Diabetes. 2023;14(4):396-411.
Milani SA, Lopez DS, Downer B, Samper-Ternent R, Wong R. Effects of diabetes and obesity on cognitive impairment and mortality in older mexicans. Arch Gerontol Geriatr. 2022;99:104581.
Cardoso S, Moreira PI. Diabesity and brain disturbances: a metabolic perspective. Mol Aspects Med. 2019;66:71-79.
Caruso I, Di Gioia L, Di Molfetta S, et al. Glucometabolic outcomes of GLP-1 receptor agonist-based therapies in patients with type 2 diabetes: a systematic review and network meta-analysis. eClinicalMedicine. 2023;64:102181.
Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-2232.
Campos-Nonato I, Galván-Valencia Ó, Hernández-Barrera L, Oviedo-Solís C, Barquera S. Prevalencia de obesidad y factores de riesgo asociados en adultos mexicanos: resultados de la Ensanut 2022. Salud Publica Mex. 2023;65:s238-s247.
Basto-Abreu A, López-Olmedo N, Rojas-Martínez R, et al. Prevalencia de prediabetes y diabetes en México: Ensanut 2022. Salud Publica Mex. 2023;65:s163-s168.
Abdi Dezfouli R, Mohammadian Khonsari N, Hosseinpour A, Asadi S, Ejtahed HS, Qorbani M. Waist to height ratio as a simple tool for predicting mortality: a systematic review and meta-analysis. Int J Obes (Lond). 2023;47(12):1286-1301.
Yang JJ, Yu D, Wen W, et al. Association of diabetes with all-cause and cause-specific mortality in Asia: a pooled analysis of more than 1 million participants. JAMA Netw Open. 2019;2(4):e192696.
Zhong P, Tan S, Zhu Z, et al. Normal-weight central obesity and risk of cardiovascular and microvascular events in adults with prediabetes or diabetes: Chinese and British cohorts. Diabetes Metab Res Rev. 2023;39(8):e3707.
Mehrabani-Zeinabad K, Haghighatdoost F, Mohammadifard N, et al. Impact of diabesity phenotype on cardiovascular diseases, major cardiovascular events and all-cause mortality. Sci Rep. 2023;13(1):11266.
Tapia-Conyer R, Kuri-Morales P, Alegre-Diaz J, et al. Cohort profile: the Mexico City prospective study. Int J Epidemiol. 2006;35(2):243-249.
Mikkelsen L, Phillips DE, AbouZahr C, et al. A global assessment of civil registration and vital statistics systems: monitoring data quality and progress. Lancet. 2015;386(10001):1395-1406.
Alegre-Diaz J, Herrington W, Lopez-Cervantes M, et al. Diabetes and cause-specific mortality in Mexico City. N Engl J Med. 2016;375(20):1961-1971.
Network E. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Accessed November 4, 2021. https://www.equator-network.org/?post_type=eq_guidelines&eq_guidelines_study_design=observational-studies&eq_guidelines_clinical_specialty=0&eq_guidelines_report_section=0&s=+&eq_guidelines_study_design_sub_cat=0
Herrington WG, Alegre-Díaz J, Wade R, et al. Effect of diabetes duration and glycaemic control on 14-year cause-specific mortality in Mexican adults: a blood-based prospective cohort study. Lancet Diabetes Endocrinol. 2018;6(6):455-463.
Dramé M, Godaert L. The obesity paradox and mortality in older adults: a systematic review. Nutrients. 2023;15(7):1780.
Gnatiuc L, Alegre-Díaz J, Wade R, et al. General and abdominal adiposity and mortality in Mexico City: a prospective study of 150 000 adults. Ann Intern Med. 2019;171(6):397-405.
Sattar N, Rawshani A, Franzén S, et al. Age at diagnosis of type 2 diabetes mellitus and associations with cardiovascular and mortality risks. Circulation. 2019;139(19):2228-2237.
Wang Y, O'Neil A, Jiao Y, et al. Sex differences in the association between diabetes and risk of cardiovascular disease, cancer, and all-cause and cause-specific mortality: a systematic review and meta-analysis of 5,162,654 participants. BMC Med. 2019;17(1):136.
Lozano-Esparza S, López-Ridaura R, Ortiz-Panozo E, et al. Diabetes is associated with a higher risk of mortality among women in a middle-income country: results form the Mexican teacher's cohort study. Diabetes Metab. 2020;46(4):304-310.
Anderson EJ, Lustig ME, Boyle KE, et al. Mitochondrial H2O2 emission and cellular redox state link excess fat intake to insulin resistance in both rodents and humans. J Clin Invest. 2009;119(3):573-581.
Xourafa G, Korbmacher M, Roden M. Inter-organ crosstalk during development and progression of type 2 diabetes mellitus. Nat Rev Endocrinol. 2023;20:27-49.
Hocking S, Samocha-Bonet D, Milner KL, Greenfield JR, Chisholm DJ. Adiposity and insulin resistance in humans: the role of the different tissue and cellular lipid depots. Endocr Rev. 2013;34(4):463-500.
Boonpor J, Pell JP, Ho FK, Celis-Morales C, Gray SR. In people with type 2 diabetes, sarcopenia is associated with the incidence of cardiovascular disease: a prospective cohort study from the UK biobank. Diabetes Obes Metab. 2023;25:1900-1910.
Escamilla-Nuñez MC, Castro-Porras L, Romero-Martinez M, Zárate-Rojas E, Rojas-Martínez R. Detección, diagnóstico previo y tratamiento de enfermedades crónicas no transmisibles en adultos mexicanos. Ensanut 2022. Salud Publica Mex. 2023;65:s153-s162.
Evia-Viscarra ML, Guardado-Mendoza R, Rodea-Montero ER. Clinical and metabolic characteristics among Mexican children with different types of diabetes mellitus. PLoS One. 2016;11(12):e0168377.
Popkin BM, Adair LS, Ng SW. Global nutrition transition and the pandemic of obesity in developing countries. Nutr Rev. 2012;70(1):3-21.
Jackson JM, DeFor TA, Crain AL, et al. Validity of diabetes self-reports in the Women's Health Initiative. Menopause. 2014;21(8):861-868.